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Abstract
We describe a case of Saccharomyces boulardii fugaemia in a
critically ill patient with septic shock treated with a probiotic agent
containing this yeast. We attributed this fugaemia to gut
translocation. Our use of caspofugin yielded excellent results.
Saccharomyces boulardii is frequently used in critically ill
patients to treat diarrhoea, and it is the only yeast probiotic
that has been proved to be effective in double-blind studies
[1,2]. Although it is considered a safe biotherapeutic agent,
the incidence of fungaemia has increased in recent years [3].
A 56-year-old male patient was transferred to our intensive
care unit with pneumonia and septic shock. Five days
previously he had been intubated and admitted to the
coronary care unit because of acute pulmonary oedema.
Despite antibiotic treatment and supportive therapy in the
intensive care unit, fever continued and both Acinetobacter
baumannii and  Klebsiella pneumoniae were isolated from
bronchial secretions. Catheter-tip culture of the central
venous catheter remained sterile. The patient then developed
major diarrhoea (four to eight liquid stools per day). His
serum was negative for Clostridium difficile toxin, and stool
culture did not reveal any pathogens. Treatment with Ultra
Levure (S. boulardii, Biocodex, Beauvais, France) 500 mg
four times daily via feeding tube was started.
One week later, two blood cultures were found to be positive.
A saccharomyces strain was identified as Saccharomyces
cerevisiae. Susceptibility testing indicated the presence of a
strain susceptible to caspofungin, treatment with which was
initiated. The patient then improved and four subsequent
blood cultures were found to be sterile. Sequencing analysis
on the DNA of the strain isolated as S. cerevisiae, as well as
the isolate of S. boulardii obtained from the commercially
available product, revealed 98% correspondence, which is
considered almost absolute identity. Given the micro-
biological finding that S. cerevisiae is undistinguishable from
S. boulardii, we believe that fungaemia was a consequence
of treatment with this yeast [4].
Three hypotheses have been reported for the pathogenesis
of S. boulardii fungaemia [2]: yeast translocation across the
gut mucosa, contamination of central venous catheter and
massive colonization. Our patient’s fungaemia was probably
the result of translocation of S. boulardii as a consequence of
septic shock and intestinal ischaemia.
S. boulardii fungaemia is usually treated with amphotericin B
or fluconazole. We admininstered caspofungin with excellent
results. This is the first case in the literature of S. boulardii
being treated with caspofungin.
We conclude that the incidence of S. boulardii fungaemia is
probably underestimated in critically ill patients. When a
patient is treated with S. boulardii, health care professionals
must wear gloves when they open the drug packaging and
must do so outside the patient’s room. The potential
therapeutic benefit of S. boulardii should carefully be
evaluated in patients with septic shock. If contamination of
vascular catheters is suspected, then removal of the central
catheter should be considered.
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